

Tanya M Wildes, Msci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3103878/publications.pdf>

Version: 2024-02-01

183
papers

4,490
citations

145106

33
h-index

145109

60
g-index

185
all docs

185
docs citations

185
times ranked

5572
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. <i>Blood Cancer Journal</i> , 2022, 12, 17.	2.8	5
2	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	0.6	17
3	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	2.8	5
4	Circumstances around falls in older adults with Cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 91-95.	0.5	4
5	Research priorities on falls in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 157-159.	0.5	4
6	Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment. <i>Supportive Care in Cancer</i> , 2021, 29, 21-33.	1.0	27
7	Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e152-e159.	0.2	14
8	Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. <i>Leukemia and Lymphoma</i> , 2021, 62, 387-398.	0.6	20
9	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. <i>Journal of Geriatric Oncology</i> , 2021, 12, 235-238.	0.5	9
10	Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 508-514.	0.5	12
11	Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". <i>Annals of Hematology</i> , 2021, 100, 1261-1266.	0.8	7
12	Geriatric oncology: this must be just like livinâ€™™ in paradise. <i>Geriatrics Gerontology and Aging</i> , 2021, 15, .	0.3	0
13	Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 608-618.	0.8	72
14	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
15	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	1.3	2
16	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
17	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2021, 12, 499-507.	0.5	7
18	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.	0.6	4

#	ARTICLE	IF	CITATIONS
19	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3043-3046.	0.6	1
20	Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e266-e274.	1.8	3
21	Addition by subtraction. <i>Blood</i> , 2021, 137, 3005-3006.	0.6	0
22	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1233-1239.	0.5	5
23	Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1005-1009.	0.5	4
24	Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e714-e721.	0.2	9
25	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 78-92.	157.7	230
26	A comprehensive approach to therapy of haematological malignancies in older patients. <i>Lancet Haematology</i> , 2021, 8, e840-e852.	2.2	17
27	Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. <i>Haematologica</i> , 2021, 106, 1991-1994.	1.7	6
28	Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. <i>Lancet, The</i> , 2021, 398, 1894-1904.	6.3	250
29	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	0.6	20
30	Autologous stem cell transplant in older patients (age \leq 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 93-99.	0.5	15
31	Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. <i>Journal of Geriatric Oncology</i> , 2020, 11, 179-183.	0.5	5
32	Cost differential associated with hospice use among older patients with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 88-92.	0.5	7
33	A comparison of three different approaches to defining frailty in older patients with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 311-315.	0.5	19
34	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1188-1190.	1.3	1
35	Educating healthcare providers in geriatric oncology â€“ A call to accelerate progress through identifying the gaps in knowledge. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1023-1027.	0.5	14
36	Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 98-104.e1.	0.2	16

#	ARTICLE	IF	CITATIONS
37	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER Medicare database. <i>Cancer</i> , 2020, 126, 808-813.	2.0	23
38	Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions. <i>JCO Oncology Practice</i> , 2020, 16, e92-e99.	1.4	12
39	Returning to life activities after hematopoietic cell transplantation in older adults. <i>Journal of Geriatric Oncology</i> , 2020, 11, 304-310.	0.5	3
40	Screening for cognitive impairment in older adults with hematological malignancies using the Montreal Cognitive Assessment and neuropsychological testing. <i>Journal of Geriatric Oncology</i> , 2020, 11, 297-303.	0.5	10
41	Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 106.	1.2	27
42	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e937-e943.	0.2	6
43	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
44	Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1279-1284.	0.5	10
45	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
46	<p>Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 619-633.	1.3	10
47	Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 647-651.	0.2	15
48	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1274-1278.	0.5	12
49	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	0.8	12
50	Frailty in Older Adults With Multiple Myeloma: A Study of US Veterans. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 117-127.	1.0	21
51	Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. <i>Journal of Geriatric Oncology</i> , 2020, 11, 753-760.	0.5	34
52	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 764-768.	0.5	26
53	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2335-2345.	2.0	28
54	Simplified frailty assessment tools: are we really capturing frailty or something else?. <i>Leukemia</i> , 2020, 34, 1967-1969.	3.3	11

#	ARTICLE	IF	CITATIONS
55	Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
56	A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
57	Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL). <i>Blood</i> , 2020, 136, 6-7.	0.6	0
58	Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study. <i>Blood</i> , 2020, 136, 13-13.	0.6	1
59	A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
60	Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
61	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. <i>Journal of Geriatric Oncology</i> , 2019, 10, 479-485.	0.5	64
62	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	2.0	112
63	A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e521-e525.	0.2	4
64	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e353-e354.	0.2	7
65	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 285-289.	0.2	17
66	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	1.8	36
67	Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 488-496.e6.	0.2	14
68	Geriatric Oncology: Getting Even Better with Age. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 871-872.	1.3	3
69	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3776-3783.	3.2	14
70	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1228-1263.	0.8	190
71	Make time for gait speed: vital to staging the aging. <i>Blood</i> , 2019, 134, 334-336.	0.6	4
72	Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. <i>Pain</i> , 2019, 160, 1835-1846.	2.0	30

#	ARTICLE	IF	CITATIONS
73	SIOG guidelines- essential for good clinical practice in geriatric oncology. Journal of Geriatric Oncology, 2019, 10, 196-198.	0.5	14
74	Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991.	1.3	42
75	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood, 2019, 134, 691-691.	0.6	37
76	Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy. Blood, 2019, 134, 5886-5886.	0.6	1
77	Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood, 2019, 134, 4774-4774.	0.6	1
78	Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions. Blood, 2019, 134, 3443-3443.	0.6	0
79	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701.	0.6	0
80	The Ire of IRE1 \pm : Overexpression of IRE1 \pm at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1 \pm Expression Is Predictive of Therapy Resistance. Blood, 2019, 134, 4351-4351.	0.6	1
81	Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood, 2019, 134, 5819-5819.	0.6	0
82	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 219-224.	0.2	34
83	Tumour boards in geriatric oncology. Age and Ageing, 2018, 47, 168-170.	0.7	5
84	Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Supportive Care in Cancer, 2018, 26, 3563-3570.	1.0	23
85	An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?. Drugs and Aging, 2018, 35, 459-465.	1.3	3
86	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging, 2018, 35, 289-302.	1.3	2
87	Falls in older adults with multiple myeloma. European Journal of Haematology, 2018, 100, 273-278.	1.1	15
88	Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	27
89	Preventing Treatment-Related Functional Decline: Strategies to Maximize Resilience. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 415-431.	1.8	15
90	Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology American Society of Hematology Education Program, 2018, 2018, 88-96.	0.9	18

#	ARTICLE	IF	CITATIONS
91	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. <i>Journal of Geriatric Oncology</i> , 2018, 9, 287-290.	0.5	10
92	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364.	0.2	4
93	Fighting for the integration of geriatric principles into oncology. <i>Journal of Geriatric Oncology</i> , 2018, 9, 705-706.	0.5	18
94	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. <i>Blood</i> , 2018, 132, 2245-2245.	0.6	1
95	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 207-207.	0.6	2
96	Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2246-2246.	0.6	4
97	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. <i>Blood</i> , 2018, 132, 5666-5666.	0.6	1
98	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 2021-2021.	0.6	1
99	Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score. <i>Blood</i> , 2018, 132, 141-141.	0.6	10
100	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 1388-1388.	0.6	0
101	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4463-4463.	0.6	0
102	Disparities in Healthcare Resource Utilization for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4793-4793.	0.6	1
103	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 5627-5627.	0.6	1
104	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3439-3439.	0.6	0
105	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2017, 8, 1-7.	0.5	25
106	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2186-2194.	3.2	37
107	Racial disparities in treatment use for multiple myeloma. <i>Cancer</i> , 2017, 123, 1590-1596.	2.0	77
108	Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. <i>Medical Oncology</i> , 2017, 34, 28.	1.2	9

#	ARTICLE	IF	CITATIONS
109	Study design for vulnerable older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2017, 8, 162-164.	0.5	0
110	Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. <i>Cancer Treatment Reviews</i> , 2017, 57, 58-66.	3.4	54
111	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2017, 11, 338-345.	1.3	9
112	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 72, 26-31.	0.8	12
113	Emerging therapies for multiple myeloma: Application in older adults. <i>Journal of Geriatric Oncology</i> , 2017, 8, 413-416.	0.5	1
114	Time to Stop Saying Geriatric Assessment Is Too Time Consuming. <i>Journal of Clinical Oncology</i> , 2017, 35, 2871-2874.	0.8	121
115	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-8.	1.0	12
116	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. <i>Blood</i> , 2017, 130, 862-862.	0.6	0
117	Gaps in nutritional research among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2016, 7, 281-292.	0.5	47
118	Review of perioperative falls. <i>British Journal of Anaesthesia</i> , 2016, 117, 720-732.	1.5	15
119	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1357-1370.	2.3	82
120	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 58, 41-48.	0.8	78
121	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 61, 1-7.	0.8	18
122	Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 4807-4813.	1.0	18
123	Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1988-1995.	1.3	72
124	Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. <i>Journal of Geriatric Oncology</i> , 2016, 7, 293-304.	0.5	58
125	Fall-risk prediction in older adults with cancer: an unmet need. <i>Supportive Care in Cancer</i> , 2016, 24, 3681-3684.	1.0	22
126	Integrating a Touchscreen-Based Assessment and Screening Tool for Adults with Multiple Myeloma. <i>Blood</i> , 2016, 128, 2373-2373.	0.6	2

#	ARTICLE	IF	CITATIONS
127	A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3329-3329.	0.6	1
128	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. <i>Blood</i> , 2016, 128, 3563-3563.	0.6	2
129	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2349-2349.	0.6	0
130	Nab [®] paclitaxel [®] based compared to docetaxel [®] based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2015, 4, 481-489.	1.3	18
131	Systematic review of falls in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 70-83.	0.5	129
132	Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit. <i>Oral Oncology</i> , 2015, 51, 103-104.	0.8	2
133	Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT. <i>Journal of Radiation Oncology</i> , 2015, 4, 37-46.	0.7	0
134	High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1075-1082.	1.3	36
135	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.	0.5	47
136	Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. <i>Journal of Geriatric Oncology</i> , 2015, 6, 133-140.	0.5	48
137	Geriatric assessment as predictors of hospital readmission in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 254-261.	0.5	48
138	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2643-2649.	0.6	47
139	RTOG 0522: Huge Investment in Patients and Resources and No Benefit With Addition of Cetuximab to Radiotherapy [®] Why Did This Occur?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1223-1224.	0.8	6
140	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1153-1154.	2.0	14
141	High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?. <i>Journal of Geriatric Oncology</i> , 2015, 6, 344-345.	0.5	2
142	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. <i>Blood</i> , 2015, 126, 3200-3200.	0.6	2
143	Presenting Characteristics and Symptom Burden of Newly Diagnosed Older Multiple Myeloma Patients in the Compass Study. <i>Blood</i> , 2015, 126, 3307-3307.	0.6	1
144	The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 2115-2115.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Variations in Multiple Myeloma Disease Presentation By Race. <i>Blood</i> , 2015, 126, 5618-5618.	0.6	0
146	The Association Between Performance Status and Health-Related Quality of Life. <i>Blood</i> , 2015, 126, 3312-3312.	0.6	0
147	Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life. <i>Cancer</i> , 2014, 120, 3994-4002.	2.0	66
148	Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. <i>Ecancermedicalsecience</i> , 2014, 8, 480.	0.6	11
149	A prospective trial comparing FDG α -PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2014, 3, 1493-1501.	1.3	13
150	Predicting Geriatric Falls Following an Episode of Emergency Department Care: A Systematic Review. <i>Academic Emergency Medicine</i> , 2014, 21, 1069-1082.	0.8	105
151	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 3-12.	1.1	17
152	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 337-341.	0.6	12
153	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2531-2540.	0.8	61
154	Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2014, 50, 895-900.	0.8	20
155	Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 128-136.	2.3	47
156	Senior Adult Oncology, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 82-126.	2.3	116
157	Geriatric Assessment in Older Adults with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 1286-1286.	0.6	2
158	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. <i>Blood</i> , 2014, 124, 555-555.	0.6	24
159	Personalizing Therapy for Older Adults with Lymphoid Malignancies: Options and Obstacles. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e240-e248.	1.8	3
160	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	0.6	1
161	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 5696-5696.	0.6	0
162	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4731-4731.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	0.6	0
164	A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	2.0	31
165	Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 227-234.	0.5	108
166	Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. <i>Oncologist</i> , 2013, 18, 1074-1079.	1.9	36
167	Postradiation Osteosarcoma in an Older Prostate Cancer Survivor: Case Study and Literature Review with Emphasis on Geriatric Principles. <i>Case Reports in Oncology</i> , 2013, 6, 250-255.	0.3	2
168	Efficacy Of Bortezomib-Based Regimens With Or Without An Immunomodulatory Agent In Older Adults With Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2013, 122, 5580-5580.	0.6	0
169	Psoas Cross-Sectional Area As Radiographic Measure Of Sarcopenia Does Not Predict Overall Survival In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5326-5326.	0.6	2
170	The Senescence-Associated Secretory Phenotype In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5357-5357.	0.6	1
171	Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209.	2.3	105
172	New treatment approaches for older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2012, 3, 279-290.	0.5	5
173	Comorbidities Impact Survival in Multiple Myeloma: Analysis of the Veterans Health Administration National Database. <i>Blood</i> , 2012, 120, 760-760.	0.6	3
174	Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database. <i>Blood</i> , 2012, 120, 968-968.	0.6	1
175	The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide. <i>Blood</i> , 2012, 120, 4050-4050.	0.6	0
176	Comorbidities Influence Survival in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 3142-3142.	0.6	1
177	The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. <i>Journal of Geriatric Oncology</i> , 2010, 1, 48-56.	0.5	20
178	Drug development for recurrent and refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 529-540.	0.6	13
179	Dasatinib in relapsed or plateau-phase multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 137-140.	0.6	17
180	Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 840-846.	2.0	85

#	ARTICLE	IF	CITATIONS
181	A 54-Year-Old Man With a Rash and Pulmonary Infiltrates. Chest, 2008, 134, 1340-1343.	0.4	3
182	The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.. Blood, 2007, 110, 1182-1182.	0.6	5
183	Comparison of Outcomes in Elderly Patients with Non-Hodgkins Lymphoma Undergoing High-Dose Chemotherapy to Their Younger Counterparts: Greater Morbidity but No Significant Impact on Overall Survival.. Blood, 2005, 106, 2086-2086.	0.6	1